A systematic mapping review of therapeutic clinical trials in dengue
PLOS Neglected Tropical Diseases · 05.06.2026 · 20 (6) · e0014382
DOI: 10.1371/journal.pntd.0014382 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 05.06.2026. Verfasst von Tran Bang Huyen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam. Hauptthemen laut MEDLINE: Dengue, Clinical Trials as Topic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Foundation, Bill and Melinda Gates Foundation, National Research Foundation Singapore.
Abstract (Originalsprache)
Background
Dengue is a growing public health threat with increasing case numbers globally. Despite the substantial burden, there are no licensed therapeutics for patients with dengue. To inform the design of large-scale practice-changing clinical trials and to assess the feasibility of an individual patient data platform for meta-analysis, we conducted a systematic mapping review of clinical trials evaluating dengue therapeutics. Our aims were to characterise published and registered dengue therapeutic trials, describe their endpoints, and assess study design quality and internal validity to inform feasibility of meta-analysis and future research.
Methods
We systematically searched Ovid MEDLINE, Ovid EMBASE, WHO ICTRP and ClinicalTrials.gov for prospective clinical trials evaluating therapeutics in patients with symptomatic dengue. Two independent reviewers screened records using Covidence. Data were extracted into a REDCap database, and risk of bias was assessed using the ROB-2 and ROBINS-I tools to describe trial design rigour. Descriptive analyses summarised the interventions, trial characteristics, study populations, and primary endpoints. This systematic review was pre-registered with PROSPERO (CRD42023469022). Results & discussion A total of 121 clinical studies were identified, comprising 72 published trials and 49 registered but unpublished studies. Interventions were categorised according to the authors’ proposed mechanism of action: antiviral (n = 10), host-directed (HDT, n = 34), supportive (n = 31), or undefined (n = 46). Aside from the studies of supportive therapies (n = 31) and unpublished studies (n = 37) which were only reviewed for their primary outcomes, 53 publications remained for review of therapeutic efficacy. Methodological concerns were common – 24 of 53 published trials (45%) were classified as having high or critical risk of bias. Corticosteroids were the most frequently evaluated intervention, involving a total of 944 randomised patients. The primary endpoints used in both antiviral and HDT trials were highly heterogeneous, limiting comparability. The combination of methodological concerns and non-standardised endpoints precluded meta-analysis for any intervention. No single treatment had sufficient or consistent evidence to support recommendations for use in clinical practice.
Conclusions
Our findings highlight a remarkably sparse evidence base for dengue therapeutics and a lack of standardised, clinically meaningful endpoints. These factors have hindered progress in evaluating candidate treatments and limited the potential for individual patient data meta-analyses. Large, high-quality trials - powered for harmonised and clinically relevant endpoints - are urgently needed to advance the development of effective therapies for dengue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
- Nuffield Department of Medicine, Centre of Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom.
- Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom.
- National Centre for Infectious Diseases, Singapore, Singapore.
- Bodleian Healthcare Libraries, University of Oxford, Oxford, United Kingdom.
- Institute of Naval Medicine, Gosport, United Kingdom.
ORCID-Profile: Tran Bang Huyen
Förderung
- Medical Research Foundation
- Bill and Melinda Gates Foundation
- National Research Foundation Singapore
- Wellcome Trust
Zitieren
APA
Huyen, T. B., McBride, A., Thein, T. L., Le, K. M., Luu, T., Huy, N. Q., Harriss, E., Kain, M. J. W., Cattrall, J., Naylor, C., Chanh, H. Q., Vuong, N. L., Munblit, D., Chia, P. Y., Lam, P. K., Watson, J. A., & Yacoub, S. (2026). A systematic mapping review of therapeutic clinical trials in dengue. PLOS Neglected Tropical Diseases, 20(6), e0014382. https://doi.org/10.1371/journal.pntd.0014382
Vancouver
Huyen TB, McBride A, Thein TL, Le KM, Luu T, Huy NQ, et al. A systematic mapping review of therapeutic clinical trials in dengue. PLOS Neglected Tropical Diseases. 2026;20(6):e0014382. doi:10.1371/journal.pntd.0014382
BibTeX
@article{Huyen2026,
author = {Huyen, Tran Bang and McBride, Angela and Thein, Tun-Linn and Le, Khoi Minh and Luu, Tran and Huy, Nguyen Quang and Harriss, Eli and Kain, Matthew J W and Cattrall, Jonathan and Naylor, Caitlin and Chanh, Ho Quang and Vuong, Nguyen Lam and Munblit, Daniel and Chia, Po-Ying and Lam, Phung Khanh and Watson, James A and Yacoub, Sophie},
title = {A systematic mapping review of therapeutic clinical trials in dengue},
journal = {PLOS Neglected Tropical Diseases},
year = {2026},
volume = {20},
number = {6},
pages = {e0014382},
doi = {10.1371/journal.pntd.0014382}
}
EUVIMED